Canada markets open in 4 hours 53 minutes

Plus Therapeutics, Inc. (PSTV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.1800+0.0500 (+2.35%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.1300
Open2.1900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.1100 - 2.1900
52 Week Range0.9700 - 4.4500
Volume8,629
Avg. Volume73,874
Market Cap12.435M
Beta (5Y Monthly)0.55
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Plus Therapeutics Announces New Employment Inducement Grants

    AUSTIN, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that on May 8, 2024, it granted option awards to Charles Huang, the Company’s new Director of Capital Markets and Investor Relations. The Company agreed to grant these equity awards to Mr. Huang to induce him to commence emp

  • GlobeNewswire

    Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

    Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announced related positive top-line FORESEE clinical trial data Management to Host Conference Call May 15, 2024 at 5:00 p.m. ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a cl

  • GlobeNewswire

    Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024

    AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 15, 2024, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the finan